MarketPeel
Pricing
…
GP

Gerald T. Proehl

TENX
DIRECTOR · TENAX THERAPEUTICS, INC. · CIK 0001279191
FILING MIX · LIFETIME83%/17%
BUYS
45
SELLS
9
TOTAL VALUE
$97.6K
COMPANIES
2
ACTIVE SINCE
May 2020
HOLDINGS NOW
1,390,544
AVG SELL PX
—
TRADE KIND
SHOWING 54 / 54
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
7 backtested trades · 8 horizonsHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Gerald T. Proehl, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d7+14.29%-2.54%+1.69%-4.22%-7.61%—
14d7+100.00%+8.05%+2.72%+5.33%+6.40%—
30d7+0.00%-13.71%+1.14%-14.85%-12.94%—
60d7+0.00%-18.47%+2.49%-20.95%-23.49%—
90d7+42.86%-4.00%+6.20%-10.20%-8.74%—
180d7+42.86%-23.76%+3.72%-27.48%-53.15%—
1y7+42.86%-28.81%+6.19%-35.00%-59.61%—
2y7+42.86%+40.04%+20.19%+19.85%-98.31%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
TENX · 30,000 shares · as of Jan 9, 2026
025,00050,00075,000100,000202120222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
2026
FLOW · 45 buys / 9 sellsCOVERAGE · 26 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
DRMA
DERMATA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
1,360,544——1,360,544Aug 16, 2026Aug 18, 2026 ↗View →
DRMA
DERMATA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
170,068——170,068Aug 16, 2026Aug 18, 2026 ↗View →
DRMA
DERMATA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
170,068——292,631Aug 16, 2026Aug 18, 2026 ↗View →
DRMA
DERMATA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
1,360,544——1,360,544Aug 16, 2026Aug 18, 2026 ↗View →
DRMA
DERMATA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
170,068——170,068Aug 16, 2026Aug 18, 2026 ↗View →
DRMA
DERMATA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
1,360,544——1,360,544Aug 16, 2026Aug 18, 2026 ↗View →
TENX
TENAX THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
3,000——30,000Jan 9, 2026Jan 13, 2026 ↗View →
DRMA
DERMATA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
37,500——37,500Jan 2, 2026Jan 6, 2026 ↗View →
DRMA
DERMATA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
122,549——122,563Dec 23, 2025Dec 29, 2025 ↗View →
DRMA
DERMATA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
490,196——490,255Dec 23, 2025Dec 29, 2025 ↗View →
DRMA
DERMATA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
490,196——490,496Dec 23, 2025Dec 29, 2025 ↗View →
DRMA
DERMATA THERAPEUTICS, INC.
PURCHASE
PRESIDENT, CHAIRMAN, CEO
78,740——0Dec 23, 2025Dec 29, 2025 ↗View →
DRMA
DERMATA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
122,549——122,549Dec 23, 2025Dec 29, 2025 ↗View →
DRMA
DERMATA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
78,740——78,740Dec 23, 2025Dec 29, 2025 ↗View →
DRMA
DERMATA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
122,549——122,549Dec 23, 2025Dec 29, 2025 ↗View →
DRMA
DERMATA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
490,196——490,496Dec 23, 2025Dec 29, 2025 ↗View →
TENX
TENAX THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
80,000——80,000Jul 1, 2025Jul 3, 2025 ↗View →
DRMA
DERMATA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
787,402——787,402Jan 21, 2025Jan 23, 2025 ↗View →
DRMA
DERMATA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
787,402——799,508Jan 21, 2025Jan 23, 2025 ↗View →
DRMA
DERMATA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
45,000——45,000Jan 13, 2025Jan 14, 2025 ↗View →
TENX
TENAX THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
100,000——100,000Dec 10, 2024Dec 12, 2024 ↗View →
TENX
TENAX THERAPEUTICS, INC.
PURCHASE
16,660——16,660Aug 8, 2024Aug 8, 2024 ↗View →
TENX
TENAX THERAPEUTICS, INC.
PURCHASE
31,654——31,654Aug 8, 2024Aug 8, 2024 ↗View →
TENX
TENAX THERAPEUTICS, INC.
PURCHASE
1,666——1,667Aug 8, 2024Aug 8, 2024 ↗View →
DRMA
DERMATA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
125,000——125,000Jan 4, 2024Jan 5, 2024 ↗View →
TENX
TENAX THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
5,000——5,000Jun 9, 2022Jun 10, 2022 ↗View →
DRMA
DERMATA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
4,517——4,517Jan 3, 2022Jan 5, 2022 ↗View →
DRMA
DERMATA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
42,141——42,141Jan 3, 2022Jan 5, 2022 ↗View →
DRMA
DERMATA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
197,610——197,610Jan 3, 2022Jan 5, 2022 ↗View →
DRMA
DERMATA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
57,859——57,859Jan 3, 2022Jan 5, 2022 ↗View →
DRMA
DERMATA THERAPEUTICS, INC.
PURCHASE
President, CEO and Chairman
20,000$2.40$48.0K59,512Nov 23, 2021Nov 26, 2021 ↗View →
DRMA
DERMATA THERAPEUTICS, INC.
PURCHASE
President, CEO and Chairman
1,247,904——2,819,904Aug 17, 2021Aug 17, 2021 ↗View →
DRMA
DERMATA THERAPEUTICS, INC.
SALE
President, CEO and Chairman
120,481——0Aug 17, 2021Aug 17, 2021 ↗View →
DRMA
DERMATA THERAPEUTICS, INC.
SALE
President, CEO and Chairman
60,240——0Aug 17, 2021Aug 17, 2021 ↗View →
DRMA
DERMATA THERAPEUTICS, INC.
PURCHASE
President, CEO and Chairman
111,951——1,390,415Aug 17, 2021Aug 17, 2021 ↗View →
DRMA
DERMATA THERAPEUTICS, INC.
SALE
President, CEO and Chairman
573,750——0Aug 17, 2021Aug 17, 2021 ↗View →
DRMA
DERMATA THERAPEUTICS, INC.
PURCHASE
President, CEO and Chairman
85,640——2,905,544Aug 17, 2021Aug 17, 2021 ↗View →
DRMA
DERMATA THERAPEUTICS, INC.
PURCHASE
President, CEO and Chairman
181,585——1,572,000Aug 17, 2021Aug 17, 2021 ↗View →
DRMA
DERMATA THERAPEUTICS, INC.
SALE
President, CEO and Chairman
1,755,622——0Aug 17, 2021Aug 17, 2021 ↗View →
DRMA
DERMATA THERAPEUTICS, INC.
PURCHASE
President, CEO and Chairman
8,928——8,928Aug 17, 2021Aug 17, 2021 ↗View →
DRMA
DERMATA THERAPEUTICS, INC.
PURCHASE
President, CEO and Chairman
27,987——27,987Aug 17, 2021Aug 17, 2021 ↗View →
DRMA
DERMATA THERAPEUTICS, INC.
SALE
President, CEO and Chairman
241,325——0Aug 17, 2021Aug 17, 2021 ↗View →
DRMA
DERMATA THERAPEUTICS, INC.
PURCHASE
President, CEO and Chairman
361,147——1,278,464Aug 17, 2021Aug 17, 2021 ↗View →
DRMA
DERMATA THERAPEUTICS, INC.
PURCHASE
President, CEO and Chairman
35,767——35,767Aug 17, 2021Aug 17, 2021 ↗View →
DRMA
DERMATA THERAPEUTICS, INC.
SALE
President, CEO and Chairman
2,436,657——0Aug 17, 2021Aug 17, 2021 ↗View →
DRMA
DERMATA THERAPEUTICS, INC.
SALE
President, CEO and Chairman
25,582,050——0Aug 17, 2021Aug 17, 2021 ↗View →
DRMA
DERMATA THERAPEUTICS, INC.
SALE
President, CEO and Chairman
3,722,500——0Aug 17, 2021Aug 17, 2021 ↗View →
DRMA
DERMATA THERAPEUTICS, INC.
PURCHASE
President, CEO and Chairman
17,857——17,857Aug 17, 2021Aug 17, 2021 ↗View →
DRMA
DERMATA THERAPEUTICS, INC.
PURCHASE
President, CEO and Chairman
142,857——152,857Aug 17, 2021Aug 17, 2021 ↗View →
DRMA
DERMATA THERAPEUTICS, INC.
SALE
President, CEO and Chairman
2,295,000——0Aug 17, 2021Aug 17, 2021 ↗View →
DRMA
DERMATA THERAPEUTICS, INC.
PURCHASE
President, CEO and Chairman
142,857——142,857Aug 17, 2021Aug 17, 2021 ↗View →
DRMA
DERMATA THERAPEUTICS, INC.
PURCHASE
President, CEO and Chairman
10,000$4.96$49.6K10,000Aug 16, 2021Aug 17, 2021 ↗View →
TENX
TENAX THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
5,000——5,000Jun 10, 2021Jun 15, 2021 ↗View →
TENX
TENAX THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
500——500May 1, 2020May 15, 2020 ↗View →
Other insiders · TENX
Loading peer insiders…
About this filer
CIK 0001279191
ROLE
Director
PRIMARY
TENX
COMPANIES
2
ACTIVE SINCE
May 2020
MARKETPEEL · /INSIDER/0001279191DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback